Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
A Phase I Study Combining Escalating Doses of Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to Establish Mixed or Full Donor Chimerism for Elderly Patients With Advanced Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
A Phase I Study Combining Escalating Doses of Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to Establish Mixed or Full Donor Chimerism for Elderly Patients With Advanced Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Suburban Hospital
mi
from
Bethesda, MD
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Suburban Hospital
mi
from
Bethesda, MD
Click here to add this to my saved trials
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
OHSU Knight Cancer Institute
mi
from
Portland, OR
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Baylor Medical Center at Garland
mi
from
Garland, TX
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Baylor Medical Center at Garland
mi
from
Garland, TX
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Universitaet Leipzig
mi
from
Leipzig,
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Universitaet Leipzig
mi
from
Leipzig,
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia
Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Aplastic Anemia
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia
Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Aplastic Anemia
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia
Evaluation of Potential Synergy of Combining Hydroxyurea With Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia
Evaluation of Potential Synergy of Combining Hydroxyurea With Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia
A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia
A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease
Atorvastatin Therapy To Improve Endothelial Function in Sickle Cell Disease
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease
Atorvastatin Therapy To Improve Endothelial Function in Sickle Cell Disease
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
OHSU Knight Cancer Institute
mi
from
Portland, OR
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Universitaet Leipzig
mi
from
Leipzig,
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Universitaet Leipzig
mi
from
Leipzig,
Click here to add this to my saved trials
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
Evaluation of Synergy of Combining Hydroxyurea With Recombinant Human Erythropoietin Glycoform Alpha (Rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
Evaluation of Synergy of Combining Hydroxyurea With Recombinant Human Erythropoietin Glycoform Alpha (Rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
University of South Alabama
mi
from
Mobile, AL
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
University of South Alabama
mi
from
Mobile, AL
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
University of California Davis
mi
from
Davis, CA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
University of California Davis
mi
from
Davis, CA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital and Research Center at Oakland & Summit Medical Center
mi
from
Oakland, CA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital and Research Center at Oakland & Summit Medical Center
mi
from
Oakland, CA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Oakland
mi
from
Oakland, CA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Health Sciences Center
mi
from
Denver, CO
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Health Sciences Center
mi
from
Denver, CO
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Kosair Children's Hospital
mi
from
Louisville, KY
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Kosair Children's Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hospital/Harvard Medical School
mi
from
Boston, MA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hospital/Harvard Medical School
mi
from
Boston, MA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Boston Med Ctr
mi
from
Boston, MA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Wayne State University
mi
from
Detroit, MI
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center, The Children's Hospital at Montefiore
mi
from
Bronx, NY
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center, The Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati Hospital
mi
from
Cincinnati, OH
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Hospital
mi
from
Memphis, TN
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated:  12/31/1969
University of Texas Parkland Health & Hospital System
mi
from
Dallas, TX
Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
The Epidemiology of Priapism (Sickle Cell Disease)
Status: Enrolling
Updated: 12/31/1969
University of Texas Parkland Health & Hospital System
mi
from
Dallas, TX
Click here to add this to my saved trials